Thick-film technology for ultra high vacuum interfaces of micro-structured traps

We adopt thick-film technology to produce ultra high vacuum compatible interfaces for electrical signals. These interfaces permit voltages of hundreds of Volts and currents of several Amperes and allow for very compact vacuum setups, useful in quantum optics in general, and especially for quantum information and quantum simulations using miniaturized traps for ions or neutral atoms. Such printed circuits can also be useful as pure in-vacuum devices. We demonstrate a specific interface, which provides eleven current feedthroughs, more than 70 dc feedthroughs and a feedthrough for radio frequencies. We achieve a pressure in the low 1e-11mbar range and demonstrate the full functionality of the interface by trapping chains of cold ytterbium ions, which requires all of the signals mentioned above being present. In addition, a versatile multi-channel device for supplying precise time-dependent voltages has been developed.Comment: 8 pages, 7 figures added references to recent literature about microwave anipulated ions and fast shuttlin

The Impact of Comparisons on the Satisfaction of Interscholastic Coaches of Girls’ Sports

According to previous work in the coaching field, job satisfaction has been found to be an important work related variable, critical to retention and turnover of female coaches [Chelladurai, P., and E. Ogasawara. (2003). “Satisfaction and Commitment of American and Japanese Collegiate Coaches.” Journal of Sport Management 17, 62–73; Sagas, M., and F.B. Ashley. (2001). “Gender Differences in the Intent to Leave Coaching: Testing the Role of Personal, External, and Work-Related Variables.” International Journal of Sport Management 2(4), 297–313]. The current study provides a better understanding of the work environment of coaches of girls’ sports by combining satisfaction and comparisons used in this process. Male and female coaches (n=202) employed full-time at Texas public high schools completed a questionnaire containing the Job Descriptive Index [Smith, P.C., L.M. Kendall, and C.C. Hulin. (1969). The Measurement of Satisfaction in Work and Retirement. New York: Rand McNally.], the Job In General (Ironson et al., 1997), a referent comparison instrument, and demographic information. The findings indicated significant satisfaction differences based on gender and comparison other. Copyright Springer Science + Business Media, Inc. 2005job satisfaction, coaching, referent comparisons, interscholastic,

The inevitable pain of software development: Why there is no silver bullet

Abstract. A variety of programming accidents, i.e., models, methods, artifacts, and tools, are examined to determine that each has a step that programmers find painful enough that they habitually avoid or postpone the step. This pain is generally where the programming accident meets requirements, the essence of software, and their relentless volatility. Hence, there is no silver bullet.

Targeted therapy in renal cancer

Renal cell cancer (RCC) has an increasing incidence internationally and is a disease for which there have been limited therapeutic options until recently. The last decade has seen a vastly improved understanding of the biological and clinical factors that predict the outcome of this disease. We now understand some of the different molecular underpinnings of renal clear cell carcinoma by mutation or silencing of the von Hippel Lindau (VHL) gene and subsequent deregulated proliferation and angiogenesis. Survival in advanced disease is predicted by factors (performance status, anemia, hypercalcemia, and serum lactate dehydrogenase, time from diagnosis to recurrence) incorporated into the Memorial Sloan Kettering Cancer Center (MSKCC) criteria (also referred to as ‘Motzer’ criteria). These criteria allow classification of patients with RCC into good, intermediate and poor risk categories with median overall survivals of 22 months, 12 months and 5.4 months, respectively. Predicated upon these advances, six new targeted drugs (sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab and pazopanib) have been tested in well-designed phase III trials, selected or stratified for MSKCC risk criteria, with positive results. All of these new drugs act at least in part through vascular endothelial growth factor (VEGF) mediated pathways with other potential therapeutic impact on platelet-derived growth factor (PDGF), raf kinase and mammalian target of rapamycin (mTOR) pathways. Importantly, data from each of these trials show a consistent doubling of progression-free survival (PFS) over prior standard of care treatments. In addition, sorafenib, sunitinib and temsirolimus, have demonstrated significant overall survival (OS) benefits as well; further follow-up is required to determine whether the disease control exhibited by everolimus and pazopanib will translate into a survival advantage. These drugs are generally well tolerated, as demonstrated by quality-of-life improvement in clinical trials, and result in clinical benefit for in excess of 70% of patients treated. They have challenged the traditional outcomes of clinical trial design by achieving their benefits with relatively few radiographic responses, but high rates of disease stability. The unique side-effect profile coupled with the chronicity of therapy requires increased vigilance to maximize exposure to the drugs while maintaining quality of life and minimizing toxicity. This review focuses on the background, clinical development and practical use of these new drugs in RCC